Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for antibiotics
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on antibiotics or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on antibiotics and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Antibiotics also referred to as antibacterial are a type of medicine that prevents the growth of bacteria. As such they are used to treat infections caused by bacteria. They kill or prevents bacteria from spreading.
Antibiotics are vital in modern day medicine; they are among the most frequently prescribed drug. There are over a 100 types of antibiotics, the main types and most commonly prescribed are penicillin, cephalosporin, macrolides, fluoroquinolone and tetracycline. They tend to be classified by mechanism of action. So, those that target the bacterial cell wall (penicillins and cephalosporins) or the cell membrane (polymyxins), or interfere with essential bacterial enzymes (rifamycins, lipiarmycins, quinolones, and sulfonamides) have bactericidal activities. Antibiotics such as macrolides, lincosamides and tetracyclines inhibit protein synthesis.
Antibiotics can all be defined by their specificity. “Narrow-spectrum” antibiotics target specific types of bacteria, for instance gram-negative (-ve) or gram-positive (+ve), whereas broad-spectrum antibiotics affect a wide range of bacteria.
Antibiotics are increasingly suffering from antibiotic resistance caused by bacterial mutations meaning the bacteria evolves to not be sensitive to the specific antibiotics being used.
Clinical trials are important to the development and understanding of antibiotics and their side effects. Although they are deemed safe, over use of the drug can kill good bacteria and lead to antibiotic resistance. This halts the ability of bacteria and microorganisms to resist the effects of the antibiotic. Clinical trials and research allow scientists and medical professionals to study the effects and develop new antibiotics.
bath emollient compared with non-antiseptic bath emollient for infected eczema 14 Rationales 15 Treatment 15 Advice 17 Reassessment 18 Referral and seeking specialist advice 19 Choice of antibiotic 19 Treatment 21 Context 22 Summary of the evidence 23 Antimicrobials 23 Choice of antibiotics 26 Course length 27 Route of administration 27 Other considerations 28 Medicines safety 28 Medicines adherence 28 Resource implications 28 Secondary bacterial infection of eczema and other common skin conditions (...) in conjunction with CG57. Overview Overview This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema, and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis. This guideline updates and replaces some recommendations on managing infections in the NICE guideline on atopic eczema
, Patient Support Manager, Antibiotic Research UK ? Ms Liz Collison, OPAT Nurse Specialist, NHS Greater Glasgow and Clyde SHTG Recommendation | 43 ? Dr Felicity Drummond, Senior Project Manager, British Society for Antimicrobial Chemotherapy ? Dr Stephanie Dundas, Consultant in Infectious Disease, NHS Lanarkshire ? Ms Sharon Falconer, OPAT Nurse Specialist, NHS Grampian ? Mr James Findlay, SAPG Public Partner, Healthcare Improvement Scotland ? Mr Mark Gilchrist, Co-lead of the British Society (...) for Antimicrobial Chemotherapy Outpatient Parenteral Antibiotic Therapy Initiative, Consultant Pharmacist Infectious Diseases and Stewardship, OPAT service lead at Imperial College Healthcare NHS Trust ? Mr Alex Moody, OPAT patient ? Dr Melinda Munang, Consultant in Infectious Diseases and General Internal Medicine, NHS Dumfries and Galloway ? Ms Fiona Robb, Antimicrobial Pharmacist, NHS Greater Glasgow and Clyde ? Dr Andrew Seaton, Consultant in Infectious Disease and General Medicine, Chair of SAPG, co- lead
FSRH CEU Response to study: Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme inducing antibiotics and hormonal contraceptives 1 FSRH CEU Statement: Response to Recent Publication Aronson and Ferner, 2020 “Analysis of reports of unintended pregnancies associated with the combined use of non-enzymeinducing antibiotics and hormonal contraceptives ” 2 February 2021 Why is this statement necessary? Since oral contraception first became available (...) , there have been concerns that antibiotics might interfere with their efficacy. There is limited published evidence to inform this issue; however, most data for non-enzyme inducing antibiotics have been reassuring. The journal BMJ Evidence Based Medicine recently published a study 1 —which has received some media attention—suggesting that concomitant use of non-enzyme inducing antibiotics could reduce the effectiveness of “hormonal contraceptives”. Aronson and Ferner 1 reviewed Yellow Card reports
Regulatory Agency (MHRA) or the NICE websites for up-to-date information. Delafloxacin (Quofenix, Menarini) is a fluoroquinolone antibiotic, which is available as a powder for infusion and a tablet. It has a marketing authorisation for treating acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Advisory statement on likely place in therapy (...) delafloxacin in these circumstances, with a switch to oral treatment after 3 days if possible. T ake account of local antimicrobial resistance and seek specialist microbiological advice. Follow the recommendations on new antimicrobials in the NICE guideline on antimicrobial stewardship. Rationale Rationale The European Public Assessment Report (EPAR) for delafloxacin states that most ABSSSI remain susceptible to penicillin and beta-lactam antibiotics, but antibiotic resistance is becoming more common
obtained before starting antibiotic therapy, and who were able to have additional sets obtained within 2 hours of empirical antimicrobial administration. Severe manifestations of sepsis were defined by 2 SIRS criteria, with a suspected or confirmed infectious source, and either hypotension (systolic blood pressure <90 mm Hg) or a serum lactate level greater than 4 mmol/L. Intervention: Two sets of blood cultures (1 aerobic and 1 anaerobic culture vial in each set) were obtained before antimicrobial (...) administration from separate venipuncture sites. Patients were required to have repeated blood testing for cultures, obtained between 30 and 120 minutes after the initiation of antibiotic therapy. Primary and Secondary Outcomes: Sensitivity of blood culture results obtained after initiation of antimicrobial therapy. Sponsors: Vancouver Coastal Health, St. Paul’s Hospital Foundation Emergency Department Support Fund, the Fonds de recherche Santé–Quebec, and the Maricopa Medical Foundation. ClinicalTrials.gov
2.6.2 Systematic reviews 31 2.6.3 RCTs 31 2.6.4 Non-randomised primary studies 31 2.7 DATA EXTRACTION 32 2.8 STATISTICAL ANALYSES 32 2.9 GRADING EVIDENCE 32 2.10 FORMULATION OF RECOMMENDATIONS 35 2.11 STAKEHOLDER INVOLVEMENT 38 2.11.1 Professional associations 38 2.11.2 Patient representatives 39 2.11.3 Process 40 2.12 FINAL VALIDATION 40 3 ADVERSE EVENTS ASSOCIATED WITH THE USE OF ANTIBIOTICS 41 3.1 ANTIBACTERIAL RESISTANCE 42 3.1.1 Antibacterial resistance, a natural phenomenon 42 3.1.2 How do (...) bacteria become resistant? 42 3.1.3 How does antibiotic resistance spread? 43 3.1.4 The burden of antibacterial resistance 43 3.1.5 The prudent use of antibiotics, an essential element in the battle against antibacterial resistance 47 3.2 DISRUPTION OF THE HUMAN MICROBIOME 47 3.2.1 The human microbiome 47 KCE Report 332 Prescription of antibiotics in the dental office 3 3.2.2 Impact of antibiotics on the human microbiome 48 3.2.3 Clostridioides difficile infection following antibiotic use 48 3.3 DRUG
antibiotic that is given intravenously. It has a marketing authorisation for the treatment of infections due to aerobic gram- negative organisms in adults with limited treatment options. Advisory statement on likely place in therapy Advisory statement on likely place in therapy Cefiderocol may be an option for treating infections due to gram-negative aerobic organisms in adults who have limited treatment options, particularly when other antimicrobials have failed. T ake account of local antimicrobial (...) in clinical practice in the UK are limited. Information on resistance can be found on Public Health England's antimicrobial resistance local indicators. The SPC for cefiderocol includes details on mechanisms that may lead to resistance. The in vitro antibacterial activity of cefiderocol against normally susceptible species is not affected by most beta-lactamases, including metallo-enzymes. Cefiderocol has little or no activity against most gram-positive organisms and anaerobes. Resource implications
Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find
port or vascular access device catheter hub before and after accessing the system using 2% chlorhexidine gluconate in 70% alcohol. The hub should be cleaned for 15 seconds and allowed to dry before access. If the manufacturer's recommendations prohibit the use of alcohol with their catheter, an aqueous solution of chlorhexidine gluconate should be considered. The recommendations also state that antibiotic lock solutions and systemic antimicrobial prophylaxis should not be used routinely to prevent (...) ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections Medtech innovation briefing Published: 3 November 2020 www.nice.org.uk/guidance/mib234 pathways Summary Summary • The technology technology described in this briefing is ClearGuard HD Antimicrobial Barrier Cap. It is a central venous catheter cap with chlorhexidine acetate coated
information. Imipenem with cilastatin and relebactam (Recarbrio, Merck Sharp & Dohme B.V) is given intravenously and is a combination of a broad-spectrum carbapenem antibiotic (imipenem); an inhibitor of dehydropeptidase-I, the renal enzyme that metabolises and inactivates imipenem (cilastatin); and a beta-lactamase inhibitor (relebactam). Only imipenem has antibacterial activity. Imipenem with cilastatin and relebactam has a marketing authorisation for treating infections caused by aerobic gram-negative (...) Antimicrobial prescribing: imipenem with cilastatin and relebactam Antimicrobial prescribing: imipenem with cilastatin and relebactam Evidence summary Published: 28 October 2020 www.nice.org.uk/guidance/es30 pathways Product overview Product overview The content of this evidence summary was up-to-date in October 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date
. Journal of neurosurgery Pediatrics. 2008;2(1):25-28. Sciubba DM, Lin LM, Woodworth GF, McGirt MJ, Carson B, Jallo GI. Factors contributing to the medical costs of cerebrospinal fluid shunt infection treatment in pediatric patients with standard shunt components compared with those in patients with antibiotic impregnated components. In: Neurosurg Focus. Vol 22. United States2007:E9. Stone J, Gruber TJ, Rozzelle CJ. Healthcare savings associated with reduced infection rates using antimicrobial suture (...) bacterial catheter-related infection. Journal of neurosurgery. 1997;87(2):247-251. Pattavilakom A, Kotasnas D, Korman TM, Xenos C, Danks A. Duration of in vivo antimicrobial activity of antibiotic-impregnated cerebrospinal fluid catheters. In: Neurosurgery. Vol 58. United States2006:930-935; discussion 930-935. Albanese A, De Bonis P, Sabatino G, et al. Antibiotic-impregnated ventriculo-peritoneal shunts in patients at high risk of infection. Acta neurochirurgica. 2009;151(10):1259-1263. Aryan HE
A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis. Antibiotic therapy has been proposed as an alternative to surgery for the treatment of appendicitis.We conducted a pragmatic, nonblinded, noninferiority, randomized trial comparing antibiotic therapy (10-day course) with appendectomy in patients with appendicitis at 25 U.S. centers. The primary outcome was 30-day health status, as assessed with the European Quality of Life-5 Dimensions (EQ-5D) questionnaire (scores (...) range from 0 to 1, with higher scores indicating better health status; noninferiority margin, 0.05 points). Secondary outcomes included appendectomy in the antibiotics group and complications through 90 days; analyses were prespecified in subgroups defined according to the presence or absence of an appendicolith.In total, 1552 adults (414 with an appendicolith) underwent randomization; 776 were assigned to receive antibiotics (47% of whom were not hospitalized for the index treatment) and 776
Continuous Infusion Compared with Intermittent Intravenous Infusion of Beta-Lactam Antibiotics for Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials Continuous Infusion Compared with Intermittent Intravenous Infusion of Beta-Lactam Antibiotics for Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed (...) peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Continuous Infusion Compared with Intermittent Intravenous Infusion of Beta-Lactam Antibiotics for Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials Chien-Huei Huang